Daveen Chopra discusses Edwards’ mitral and tricuspid focus, PASCAL and EVOQUE, and patient impacts

In the inaugural episode of our newest podcast, Structural Heart Talks, we sit down with Daveen Chopra, Corporate VP and GM of Transcatheter Mitral and Tricuspid Therapies (TMTT) at Edwards Lifesciences. In the episode, Chopra discusses the unique challenges of advancing therapies for the mitral and tricuspid valves, which have historically been more difficult to treat than the aortic valve due to their complex and varied nature. He details Edwards Lifesciences' efforts to innovate in this space with technologies like the PASCAL valve repair system and the EVOQUE tricuspid valve replacement system, the first transcatheter tricuspid valve replacement approved in both the US and Europe. Later, Chopra explains the importance of a focused approach at Edwards Lifesciences, where the company’s specialization in structural heart disease enables deeper knowledge and more targeted innovation. The conversation also explores the intricate process of planning and executing these advanced procedures, which require close collaboration between interventional cardiologists and echocardiographers. Chopra underscores the ongoing commitment to clinical evidence and real-world outcomes as key drivers of future success in this rapidly evolving field. Looking ahead, he emphasizes the need to increase awareness, diagnosis, and treatment rates for valve diseases, noting that many patients still go untreated due to a lack of awareness. Thank you to Resonetics for sponsoring this episode of Structural Heart Talks. To learn more about how Resonetics supports medical device companies, visit: https://shorturl.at/E1wO8 Thank you for listening to the Structural Heart Talks podcast. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks or the Structural Heart Talks on YouTube Podcasts to ensure you never miss an episode.

There are no comments yet.

Please log in to write the first comment.